Padsevonil (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, JANTooltip Japanese Accepted Name; developmental code name UCB-0942) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of epilepsy.

[1][3][2] It is much more potent than earlier SV2A ligands like levetiracetam and brivaracetam.

[2] However, in contrast to its predecessors, padsevonil's chemical structure has been modified such that it is no longer a racetam.

[2] In addition, padsevonil also interacts with synaptic vesicle glycoprotein 2B (SV2B) and 2C (SV2C).

[1][3] As of November 2023, it is in phase 2 clinical trials.